GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Vanguard Health Care Fund Buys ACL, NUVA, SLXP, DF, VRTX, AMGN, ZMH, Sells ENR, GENZ, NVS

insider

gurufocus

341 followers
If you have health care stocks in your portfolio, you should certainly look at Edward Owens is doing with health care stocks. Mr. Owens averaged 16.5% a year since the fund incepted in 1984. Over the past 10 years, the average health care funds returned 1.73% a year, while Mr. Owens’ fund gained 4.82% a year.

As of 12/31/2010, Vanguard Health Care Fund owns 79 stocks with a total value of $18.4 billion. These are the details of the buys and sells.

For the details of Edward Owens's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Edward+Owens

This is the sector weightings of his portfolio:

Health Care 38.5%
Consumer Services 7.9%
Technology 2.3%
Industrials 0.7%


These are the top 5 holdings of Edward Owens

  1. Merck & Co Inc (MRK) - 32,730,248 shares, 6.4% of the total portfolio. Shares reduced by 0.3%
  2. Forest Labs A (FRX) - 28,353,000 shares, 4.92% of the total portfolio. Shares reduced by 0.35%
  3. Pfizer Inc (PFE) - 43,559,788 shares, 4.14% of the total portfolio. Shares reduced by 1.58%
  4. Mckesson Corp (MCK) - 10,589,900 shares, 4.05% of the total portfolio. Shares reduced by 4.51%
  5. Unitedhealth Gp (UNH) - 18,785,100 shares, 3.68% of the total portfolio. Shares reduced by 0.53%


Added: Vertex Pharmaceuticals (VRTX)

Edward Owens added to his holdings in Vertex Pharm by 273.2%. His purchase prices were between $32.43 and $38.35, with an estimated average price of $35.02. The impact to his portfolio due to this purchase was 0.54%. His holdings were 3,893,200 shares as of 12/31/2010.

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex Pharm has a market cap of $7.9 billion; its shares were traded at around $38.89 with and P/S ratio of 77.4. Vertex Pharm had an annual average earning growth of 16.6% over the past 10 years.

Added: Amgen Inc (AMGN)

Edward Owens added to his holdings in Amgen Inc by 19.02%. His purchase prices were between $52.69 and $57.96, with an estimated average price of $55.6. The impact to his portfolio due to this purchase was 0.51%. His holdings were 10,638,455 shares as of 12/31/2010.

Amgen Inc. discovers, develops and delivers innovative human therapeutics. Amgen Inc has a market cap of $52.04 billion; its shares were traded at around $55.08 with a P/E ratio of 10.7 and P/S ratio of 3.5. Amgen Inc had an annual average earning growth of 18.1% over the past 10 years. GuruFocus rated Amgen Inc the business predictability rank of 4-star.

Added: Zimmer Holdings (ZMH)

Edward Owens added to his holdings in Zimmer Holdings by 87.5%. His purchase prices were between $47.44 and $54.97, with an estimated average price of $51.49. The impact to his portfolio due to this purchase was 0.21%. His holdings were 1,500,000 shares as of 12/31/2010.

Zimmer is a global leader in the design, development, manufacturing and market of reconstructive orthopaedic implants and fracture management products. Zimmer Holdings has a market cap of $11.68 billion; its shares were traded at around $59.16 with a P/E ratio of 13.6 and P/S ratio of 2.8. Zimmer Holdings had an annual average earning growth of 18.2% over the past 10 years.

New Purchase: Alcon Inc (ACL)

Edward Owens initiated holdings in Alcon Inc. His purchase prices were between $157.25 and $170.18, with an estimated average price of $164.25. The impact to his portfolio due to this purchase was 0.31%. His holdings were 350,000 shares as of 12/31/2010.

Alcon, Inc. is the world's eye care company. Alcon Inc has a market cap of $49.17 billion; its shares were traded at around $162.86 with a P/E ratio of 21.1 and P/S ratio of 6.8. The dividend yield of Alcon Inc stocks is 2.1%. Alcon Inc had an annual average earning growth of 18.3% over the past 10 years.

New Purchase: Nuvasive Inc (NUVA)

Edward Owens initiated holdings in Nuvasive Inc. His purchase prices were between $22.25 and $37.36, with an estimated average price of $27.53. The impact to his portfolio due to this purchase was 0.3%. His holdings were 2,130,103 shares as of 12/31/2010.

NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. Nuvasive Inc has a market cap of $1.1 billion; its shares were traded at around $27.945 with a P/E ratio of 38.3 and P/S ratio of 3.

New Purchase: Salix Pharm-ltd (SLXP)

Edward Owens initiated holdings in Salix Pharm-ltd. His purchase prices were between $35.96 and $48.61, with an estimated average price of $41.76. The impact to his portfolio due to this purchase was 0.22%. His holdings were 850,000 shares as of 12/31/2010.

Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialtypharmaceutical company focussed on the needs of physicians specializing ingastroenterology. Salix Pharm-ltd has a market cap of $2.37 billion; its shares were traded at around $40.97 with and P/S ratio of 10.2.

New Purchase: Dean Foods Co (DF)

Edward Owens initiated holdings in Dean Foods Co. His purchase prices were between $7.26 and $10.8, with an estimated average price of $8.91. The impact to his portfolio due to this purchase was 0.03%. His holdings were 700,000 shares as of 12/31/2010.

Dean Foods Company is the nation's processor and distributor of fresh milk and other dairy products, and a leader in the specialty foods industry. Dean Foods Co has a market cap of $1.85 billion; its shares were traded at around $10.15 with a P/E ratio of 10.5 and P/S ratio of 0.2.

Reduced: Genzyme-general (GENZ)

Edward Owens reduced to his holdings in Genzyme-general by 34.27%. His sale prices were between $69.65 and $72.91, with an estimated average price of $71.25. The impact to his portfolio due to this sale was -0.62%. Edward Owens still held 3,069,340 shares as of 12/31/2010.

Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. Genzyme-general has a market cap of $19 billion; its shares were traded at around $73.35 with a P/E ratio of 81.5 and P/S ratio of 4.2. Genzyme-general had an annual average earning growth of 17.5% over the past 10 years. GuruFocus rated Genzyme-general the business predictability rank of 2.5-star.

Reduced: Novartis Ag-adr (NVS)

Edward Owens reduced to his holdings in Novartis Ag-adr by 21.07%. His sale prices were between $53.41 and $59.77, with an estimated average price of $57.3. The impact to his portfolio due to this sale was -0.42%. Edward Owens still held 4,869,880 shares as of 12/31/2010.

Novartis AG is committed to improving health and well-being through innovative products and services. Novartis Ag-adr has a market cap of $127.9 billion; its shares were traded at around $55.86 with a P/E ratio of 10.8 and P/S ratio of 2.5. The dividend yield of Novartis Ag-adr stocks is 3%. Novartis Ag-adr had an annual average earning growth of 14.2% over the past 10 years. GuruFocus rated Novartis Ag-adr the business predictability rank of 5-star.

Sold Out: Energizer Hldgs (ENR)

Edward Owens sold out his holdings in Energizer Hldgs. His sale prices were between $66.37 and $75.49, with an estimated average price of $71.75.

Energizer Holdings is the world's largest manufacturer of primary batteries and flashlights and a global leader in the dynamic business of providing portable power. Energizer Hldgs has a market cap of $5.13 billion; its shares were traded at around $72.74 with a P/E ratio of 13.9 and P/S ratio of 1.2. Energizer Hldgs had an annual average earning growth of 19.1% over the past 10 years. GuruFocus rated Energizer Hldgs the business predictability rank of 3-star.

About the author:

gurufocus
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 3.3/5 (9 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK